Navigation Links
PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
Date:5/4/2010

ANNAPOLIS, Md., May 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Interim CEO, Eric I. Richman, will be participating on a special biosecurity panel presentation promoting the critical interrelationship between government, academia and industry in the development of medical countermeasures vital to our nation's biosecurity.

The panel presentation, entitled "Public Private Partnerships for State-of-the-Art Countermeasures" will be held at 4:00 pm EDT on Wednesday, May 5, 2010, as part of the inaugural 2010 Biosecurity Conference, co-located with the 2010 BIO International Conference, May 3-6, 2010, McCormick Place, Chicago, IL.  

Officials in the biodefense industry note that increasing our nation's capability to rapidly and effectively develop and produce new and better medical countermeasures might not simply prevent casualties, but reduce the likelihood of such an attack.  Panelists, which include senior government officials and leading industry representatives will assess the process for the creation of these countermeasures and analyze the successes and challenges in their development through case studies and discussion, with the goal of enhancing our biodefense readiness and strategic national arsenal.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
2. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
3. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
4. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
5. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
8. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
9. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
10. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
11. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... MO , March 29, 2017 /PRNewswire/ - The ... its partners Nordion, a business of Sterigenics International, and ... (LAR) has been submitted to the U.S. Nuclear Regulatory ... domestic U.S. production of molybdenum-99 (Mo-99). Once operational, production ... half of U.S. demand for Mo-99, which currently must ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, ... and comprehensive study on the existing state of the global Microfluidic ... Europe and Asia-Pacific , ... and Africa . ... Browse 172 Tables and Figures, 13 Major Company ...
(Date:3/28/2017)... ... ... Mass spectrometry is becoming more widely for clinical testing and evaluation of ... to perform challenging analyses in complex matrices and sample types. While mass spectrometry is ... to be routinely used for medical testing. , In this webinar, participants ...
(Date:3/28/2017)... ... March 28, 2017 , ... Ecovia Renewables, Inc. ... Research (SBIR) grant from the National Science Foundation (NSF). Under the award ... a suite of BioGelâ„¢ biopolymer materials for hygiene applications, particularly for use in ...
Breaking Biology Technology:
(Date:2/27/2017)... Strategic Cyber Ventures , the industry,s first cybersecurity focused ... investment in  Polarity , the first commercial human memory-augmentation ... and is led by cybersecurity veterans Tom Kellermann ... , also a longtime cybersecurity veteran and founder of ... round of funding. This new funding will be used ...
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
(Date:2/16/2017)... SAN FRANCISCO , Feb. 16, 2017 /PRNewswire/ ... research, today announced that it has received Laboratory ... The CAP Accreditation is presented to laboratories that ... and who demonstrate scientifically rigorous processes. ... of excellence in laboratory practices. We,re honored to ...
Breaking Biology News(10 mins):